Analysts are intrested in these 5 stocks: ( (NTR) ), ( (CAVA) ), ( (CBRL) ), ( (ADMA) ) and ( (CRSP) ). Here is a breakdown of their recent ratings and the rationale behind them.
Nutrien is drawing mixed reactions as analyst Lucy Bi cuts the stock to Hold, even while calling 2026 a likely strong year. She argues that today’s high fertilizer profits are temporary, with potash and nitrogen prices expected to ease from 2027, which could pull earnings below what the market is currently baking in.
Her thesis is that Nutrien’s potash market share looks defendable, but new global capacity and fewer supply disruptions should pressure prices and margins over time. With retail now stabilized and capital returns steady but unspectacular, she sees limited catalysts and sets a $65 target, suggesting the stock may tread water rather than break out.
CAVA Group is back in favor on Wall Street, with analyst Dennis Geiger upgrading the fast-casual chain to Buy and lifting his target to $90. He highlights CAVA’s strong same-store sales even in a weak economy and sees multiple levers—from menu innovation to digital and loyalty programs—that can keep traffic and sales growing.
Geiger also points to CAVA’s aggressive expansion, modeling mid-teens annual unit growth and hinting the chain could surpass its 1,000-store goal by 2032. With healthy new-store returns and a scarcity of credible growth stories in restaurants, he argues that CAVA’s premium valuation is justified by the potential for industry‑leading revenue and EBITDA growth.
Cracker Barrel is staging a quiet comeback, prompting analyst Anthony Trainor to upgrade the stock to Buy with a $50 target. After a tough period, recent quarterly results showed better-than-expected earnings, improving sales trends, and evidence that management’s turnaround efforts are gaining traction.
Trainor notes cost cuts, leaner operations, and a refocus on loyalty, marketing, and menu innovation as key drivers of the rebound. With short interest high, valuation still near historical trough levels, and easier comparisons ahead, he sees room for further upside as comps and EBITDA improve into fiscal 2027.
ADMA Biologics is emerging as a high-growth healthcare name, as analyst Ryan Deschner resumes coverage with a Buy rating and a $21 target. ADMA’s flagship IVIG therapy ASCENIV is aimed at patients who don’t respond to standard treatments, and its strong revenue ramp has turned the company profitable while margins have sharply improved.
Deschner believes ASCENIV is on a path to blockbuster status by the next decade, backed by real-world data suggesting fewer infections and hospitalizations. He also highlights pipeline diversification with SG-001 for pneumococcal infections and argues that recent short-seller criticism underestimates both demand and differentiation, making ADMA a higher-risk but potentially rewarding biotech play.
CRISPR Therapeutics is back in the spotlight as analyst Maxwell Skor raises the stock to Hold, setting a $60 price target and assuming coverage with a more balanced view. He sees the company’s first approved therapy, Casgevy, as a multi‑billion‑dollar opportunity but warns that much optimism is already reflected in the share price.
Skor frames CRISPR as a “show‑me” story, where investors need clearer visibility on how quickly complex gene‑editing procedures translate into recognized revenue and sustainable profits. Key milestones include broader use via gentler conditioning, progress toward profitability, and pivotal data from in vivo program CTX310 in cardiovascular disease, all supported by a solid cash cushion.


